A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PACIFIC 6
- Sponsors AstraZeneca
- 10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer.
- 24 Apr 2019 Planned End Date changed from 30 Dec 2022 to 21 Feb 2023.
- 24 Apr 2019 Planned primary completion date changed from 30 Dec 2022 to 21 Feb 2023.